{"entity":{"id":"fgf2","kind":"target","name":"FGF2","aka":["fibroblast growth factor 2","Fibroblast growth factor 2"],"tldr":"FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","summary":"Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signalling. Binds to integrin ITGAV:ITGB3.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Quizartinib. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.62, affected pathway 0.99, literature 0.99, genetic association 0.00, animal model 0.55).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3676","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3676"},{"label":"UniProt P09038","url":"https://www.uniprot.org/uniprotkb/P09038/entry"},{"label":"NCBI Gene 2247","url":"https://www.ncbi.nlm.nih.gov/gene/2247"},{"label":"Ensembl ENSG00000138685","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138685"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["angiogenic-switch"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.62; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGF2","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3676","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3676","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P09038","url":"https://www.uniprot.org/uniprotkb/P09038/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FGF2","url":"https://civicdb.org/features/1872","note":"1 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000138685","url":"https://platform.opentargets.org/target/ENSG00000138685/associations","note":"association with cancer (MONDO_0004992) 0.71;  (GraphQL API, CC0)"}],"hgnc":"HGNC:3676","ensembl":"ENSG00000138685","uniprot":"P09038","entrez":"2247","biology":"Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signalling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Can induce angiogenesis. Location: Secreted; Nucleus (UniProt). Locus 4q28.1 (HGNC).","whereFound":["Acute myeloid leukaemia: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fgf2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"pathway":[{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/"}]}}